In vivo evaluation of substituted 3-amino-1,4-benzodiazepines as anti-depressant, anxiolytic and anti-nociceptive agents

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 2, 2009, Pages 61-71

  Lattmann, Eric ^a   Lattmann, Pornthip ^a   Boonprakob, Yodchai ^b   Airarat, Wanchai ^b   Singh, Harjit ^a   Offel, Michael ^a   Sattayasai, Jintana ^b  

^a ASTON UNIVERSITY   (United Kingdom)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

1,4 benzodiazepines, template; 3 amino 5 phenyl l,4 benzo dlazeplnone; Antidepressants; Antinociceptives; Anxiolytics; CAS 604 75 1; Cholecystoklnin antagonists; Oxazepam

Indexed keywords

3 (1 BENZYLPIPERAZINE) 7 CHLORO 5 PHENYL 1,3 DIHYDRO 2H 1,4 BENZODIAZEPIN 2 ONE; 3 AMINO 1,4 BENZODIAZEPINE DERIVATIVE; 7 CHLORO 3 (3 CYCLOHEXYLAMINO) 5 PHENYL 1,3 DIHYDRO 2H 1,4 BENZODIAZEPIN 2 ONE; 7 CHLORO 3 (3 METHOXYANILINO) 5 PHENYL 1,3 DIHYDRO 2H 1,4 BENZODIAZEPIN 2 ONE; 7 CHLORO 3 (N METHYLANILINO) 5 PHENYL 1,3 DIHYDRO 2H 1,4 BENZODIAZEPIN 2 ONE; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ RECEPTOR; DESIPRAMINE; MORPHINE; OXAZEPAM; TRAMADOL; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; PAIN; REACTION ANALYSIS; STRUCTURE ANALYSIS; TRANQUILIZING ACTIVITY;

EID: 62249140239     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296366     Document Type: Article

References (29)

1. A receptors. Exp Opin Ther Patents. 1999;9:1347-52.
2. Lattmann E, Billington DC, Poyner DR. Synthesis and evaluation of asperlicin analogues as non-peptidal cholecysto-kinin-antagonists. Drug Des Discov. 2001;17:219-32.
3. Wilson TM, Henke BR, Momtahen TM. 3-[2-(N-Phenylace-tamide)]-l,5- benzodiazepines: Orally active, binding selective CCK-A agonists. J Med Chem. 1996;39:3030-8.
4. B/gastrin receptor antagonists containing a cationic solubi- lizing group. J Med Chem. 1994;37:719-31.
5. Wood MR, Homnick CF, Murphy KL. Benzodiazepines as potent and selective bradykinin Bl antagonists. J Med Chem. 2003;46:1803-17.
6. Varty GBP, Ursula C, Galen J. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology. 2002;27:371-84.
7. Sansone M, Castellano C, Pavone F. Opioid benzodizapine tifluadom and drug-induced hyperactivity in mice-lack of benzodiazepine-like effects. Pol J Pharmacol Pharm. 1985;37:585-91.
8. Petrillo P, Amato M, Tavani A. The interaction of the two isomers of the opioid benzodiazepine tifluadom with binding sites and their analgesic and intestinal effects in rats. Neuropeptides 1985;5:403-11.
9. Lattmann E, Offel M, Singh H. Aston University, PCT/GB2004/002252, 27/05/2004.
10. Roskoski R, Ritchie PA. Time-dependent inhibition of protein tarnesyl-transferase by a benzodiazepine peptide mimetic. Biochemistry. 2001;40:9329-35.
11. Sternbach LH, Reeder E. (F. Hoffmann-La Roche AG), Swiss Patent 2.233.482, 11/12/1960.
12. Stempel A, Douvan I, Reeder E. Quinazolines and 1,4-ben-zodiazepines. 4,l,5-benzoxadiazocin-2-ones, a novel ring system. J Org Chem. 1967;32:2417-22.
13. Sternbach LH, Reeder E. Quinazolines and 1,4-benzodiaze-pines. The rearrangement of 6-chloro-2-chloromethyl-4-phenylquinazoline 3-oxide into 2-amino derivatives of 7- chloro-5-phenyl-3H-l,4-benzodiazepine 4-oxide. J Org Chem. 1961;26:1111-8.
14. Avadagic A, Lesac A, Majer Z. Oxidation of quinazolines and 1,4-benzodiazepines. Helv Chim Acta. 1988;81:1567-77.
15. Cepanec I, Litvic M, Pogorelic I. Efficient synthesis of 3-hy-droxy-1,4-benzodiazepines oxazepam and lorazepam by new acetoxylation reaction of 3-position of 1 4-benzodiazepine ring. Org Proc Res Dev. 2006;10:1192-201.
16. Stempel A, Reeder E, Sternbach LH. Quinazolines and 1,4-benzodiazepines. Mechanism for ring enlargement of qui-nazoline 3-oxide with alkali to l,4-benzodiazepin-2-one dioxides. J Org Chem. 1965:30:4267-73.
17. Stempel A, Douvan I, Reeder E. Quinazolines and 1,4-ben-zodiazepines. l,5-benzoxadiazocin-2-ones, a novel ring system. J. Org. Chem.1967;32: 2417-24.
18. Satoh M, Okamoto Y, Koshio H. Biological Activity of YM022. Novel (3-amino substituted phenyl)urea derivatives of l,4-benzodiazepin-2-one as gastrin-cholecystokinin-B receptor agonists. Chem Pharm Bull. 1996:44:1412-20.
19. Kulkarni YD, Abdi SHR, Sharma VL. Synthesis of 3-substituted-amino/ arcyloxy-7-chloro-5-phenyl-l,3-dihydro-2H- l,l,4-benzodiazepin-2-ones as possible anxiolytics. J Indian Chem Soc. 1986:425-31.
20. Gatta F, Delgiudice MR, Settimj G. New synthesis of 3-(disubstituted- amino)-1,4-benzodiazepin-2-ones. Chem Comm. 1979;32:718-25.
21. Bock MG, DiPardo RM, Evans BE. Benzodiazepine gastrin and brain cholecystokinin receptor ligands. J Med Chem. 1989;32:13-26.
22. Gatta F, Delgiudice MR, Pandolfi C. Sintesi di 2-E 3-amino 1,4-benzodizepine. Farmaco. 1982;27:343-51.
23. Offel M, Lattmann P, Singh H. Synthesis of substituted 3-anilino-5-phenyl-1,3-dihydro-2H- 1,4-benzodiazepinones and their evaluation as cholecystokinin ligands. Arch Pharm. 2006;339:163-78.
24. Lattmann E, Billington DC, Poyner DR. Combinatorial solid phase synthesis of multiply-substituted 1,4-benzodiaze-pines and affinity studies on the CCK2 receptor. Drug Des Discov. 2002;18:9-21.
25. Lattmann E, Singh H, Boonprakob Y. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-lH-pyrazol-4-yl)-lH-indole-carboxamide as cholecystokinin antagonists. J Pharm Pharm. 2006;58:1-17.
26. Lattmann E, Sattayasai J, Boonprakob Y. Synthesis and evaluation of N-(5-methyl-3-oxol,2-diphenyl-2,3-dihydro- lH-pyrazol-4yl)-N-phenylureas as cholecystokinin antagonists. Arzneimittelforschung. 2005;55:251-64.
27. McCleane GJ. The cholecystokinin antagonist proglumide enhances the analgesic effect of dihydrocodeine. Clin J Pain. 2003;19:200-4.
28. McCleane GJ. A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong opioids in chronic human neuropathic pain. Neurosci Lett. 2003;338:151-63.
29. Simpson K. Management of neuropathic pain using a CCK antagonist devazepide as an adjunct to strong opiates [abstract]. In: International conference on the mechanism and treatment of neuropathic pain; 2001; San Francisco, p. 397, no. 118.